A 35-year-old man with a 6-year history of OCD presents to the outpatient clinic. He has been on sertraline 150 mg daily for 8 weeks with minimal improvement in his contamination obsessions and compulsive washing (currently spending 3–4 hours per day washing). His Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score is 32 (severe). He reports good adherence and tolerates the medication well. His wife reports that his symptoms are severely impairing his work and family functioning. What is the most appropriate next step?

Explanation

## Treatment-Resistant OCD: Diagnosis and Management **Key Point:** This patient has treatment-resistant OCD (TrOCD), defined as inadequate response to adequate SSRI dosing for adequate duration. The next step is to optimize psychotherapy (ERP) while considering pharmacological augmentation if psychotherapy alone is insufficient. ### Definition of Treatment-Resistant OCD | Criterion | Status in This Case | |-----------|---------------------| | Adequate SSRI dose (150 mg sertraline) | ✓ Yes | | Adequate duration (8 weeks) | ✓ Yes (though 12 weeks is ideal) | | Minimal response (Y-BOCS still 32) | ✓ Yes (severe symptoms persist) | | Good adherence | ✓ Yes | | Adequate tolerability | ✓ Yes | | **Conclusion** | **Treatment-resistant OCD** | **High-Yield:** The definition of "adequate SSRI trial" in OCD is **12 weeks at therapeutic dose** (not 8 weeks as in depression). However, at 8 weeks with minimal response, the prognosis is poor with SSRI monotherapy alone, and augmentation or optimization should be considered. ### Management Algorithm for Treatment-Resistant OCD ```mermaid flowchart TD A[OCD inadequately responsive to SSRI]:::outcome --> B{SSRI dose adequate?}:::decision B -->|No| C[Increase to max tolerated dose]:::action B -->|Yes| D{Duration adequate 12 weeks?}:::decision D -->|No| E[Continue current SSRI, reassess at 12 weeks]:::action D -->|Yes| F{Psychotherapy available?}:::decision F -->|No| G[Initiate ERP referral]:::action F -->|Yes| H[Intensive CBT-ERP]:::action H --> I{Response after 12-16 weeks?}:::decision I -->|Yes| J[Continue ERP + SSRI]:::action I -->|No| K[Consider augmentation]:::action K --> L[Antipsychotic aripiprazole or risperidone]:::action L --> M[Or switch to clomipramine]:::action ``` ### Why This Patient Needs Intensive ERP **Clinical Pearl:** Psychotherapy (ERP) is **underutilized** in OCD management. Many patients with "treatment-resistant" OCD have never received adequate ERP. The combination of SSRI + intensive ERP has superior outcomes to SSRI + augmentation alone. 1. **ERP is evidence-based for TrOCD** - Response rates: 50–80% with adequate ERP - Can be delivered in intensive formats (3–5 sessions per week) for faster response - Addresses the core mechanism (habituation) that SSRI alone does not fully achieve 2. **Intensive outpatient format** - More frequent sessions (3–5 per week) than standard weekly therapy - Allows for massed practice and faster habituation - Avoids hospitalization while providing intensive support 3. **Contamination obsessions with washing compulsions** - Highly responsive to ERP (exposure to contaminants without washing) - Patient can be exposed to feared contaminants and prevented from washing - Habituation typically occurs within 45–90 minutes of exposure ### Pharmacological Augmentation Strategy (If ERP Insufficient) If intensive ERP + SSRI for 12–16 weeks yields inadequate response: | Augmentation Strategy | Evidence | Mechanism | |----------------------|----------|----------| | **Antipsychotic (aripiprazole 5–15 mg, risperidone 2–6 mg)** | Strong | Dopamine antagonism; may enhance serotonergic function | | **Clomipramine monotherapy** | Moderate | Tricyclic with stronger serotonergic/noradrenergic activity than SSRIs | | **Switching SSRI** | Weak | Different pharmacokinetics; only 10–15% response if first SSRI failed | **High-Yield:** Antipsychotic augmentation (aripiprazole or risperidone) is the **most evidence-based augmentation strategy** for TrOCD, with response rates of 40–60% when added to SSRI. However, it should only be considered after adequate ERP has been attempted. ### Why Each Option Is Suboptimal at This Stage **Option 1 (Antipsychotic augmentation now):** Premature. The patient has not yet received intensive ERP. Augmentation should be reserved for cases where ERP + SSRI for 12–16 weeks has been inadequate. **Option 2 (Switch SSRI):** Weak evidence. Switching SSRIs is only beneficial if the first SSRI was inadequately dosed or the patient had poor tolerability. This patient is at therapeutic dose and tolerates it well. Response rate to a second SSRI after first-SSRI failure is only 10–15%. **Option 3 (Clomipramine monotherapy):** Discontinuing an effective SSRI to switch to clomipramine is not standard practice. Clomipramine is reserved for SSRI-refractory cases or as augmentation. Additionally, clomipramine has more anticholinergic side effects and requires cardiac monitoring. **Option 4 (Intensive ERP + consider augmentation):** **Correct.** This follows the evidence-based algorithm: optimize psychotherapy first, then add pharmacological augmentation if needed. **Warning:** Many clinicians escalate medications without ensuring the patient has received adequate psychotherapy. ERP is the most effective intervention for OCD and should be prioritized.